Skip to content

The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia

Daniel A. Arber, Attilio Orazi, Robert Paul Hasserjian, Jürgen Thiele, Michael J. Borowitz, Michelle M. Le Beau, Clara Derber Bloomfield, Mario Cazzola, James W. Vardiman

Blood · 2016 · 10,450 citationsOpen access

No retraction on record in OpenAlex.Check Crossref now

Cite this paper

Arber, D. A., Orazi, A., Hasserjian, R. P., Thiele, J., Borowitz, M. J., Beau, M. M. L., Bloomfield, C. D., Cazzola, M., & Vardiman, J. W. (2016). The 2016 revision to the world health organization classification of myeloid neoplasms and acute leukemia. Blood, 127(20), 2391–2405. https://doi.org/10.1182/blood-2016-03-643544

In text: (Arber et al., 2016)

Ask a question about this research

One question, free, no account. Anchorcite finds the papers, checks each against Crossref and links every sentence of the answer to the passage it comes from.

Abstract

The World Health Organization (WHO) classification of tumors of the hematopoietic and lymphoid tissues was last updated in 2008. Since then, there have been numerous advances in the identification of unique biomarkers associated with some myeloid neoplasms and acute leukemias, largely derived from gene expression analysis and next-generation sequencing that can significantly improve the diagnostic criteria as well as the prognostic relevance of entities currently included in the WHO classification and that also suggest new entities that should be added. Therefore, there is a clear need for a revision to the current classification. The revisions to the categories of myeloid neoplasms and acute leukemia will be published in a monograph in 2016 and reflect a consensus of opinion of hematopathologists, hematologists, oncologists, and geneticists. The 2016 edition represents a revision of the prior classification rather than an entirely new classification and attempts to incorporate new clinical, prognostic, morphologic, immunophenotypic, and genetic data that have emerged since the last edition. The major changes in the classification and their rationale are presented here.

  1. Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF12010
  2. IDH1 and IDH2 Mutations in Gliomas2009
  3. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel2016
  4. Proposals for the Classification of the Acute Leukaemias F rench ‐A merican ‐B ritish (FAB) C o‐operative G roup1976
  5. Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia2013

Metadata from OpenAlex (CC0). Citations are generated from the published record.